Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Metronidazole vs. Oral Metronidazole and Rifampin for Treatment of CDAD
NCT00182429Phase 3Completed
- Sponsor
- McMaster University
- Start
- Feb 2004
- Primary completion
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rifampicin in Clostridium difficile infection (CDI) (2 arms), sponsored by McMaster University. Primary endpoint: Time to resolution of symptoms in each treatment arm at 40 days. Started Feb 2004; status: completed.
02
Drugs
rifampicin
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT00182429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00182429.